Tevogen Bio Holdings Inc. (G28)
XFRA 
Summary
G28 Chart
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential
On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. TVGN, a clinical-stage immunotherapy company.
Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound
Initiated a small position in Tevogen Bio Holdings Inc. due to a promising pipeline and favorable seasonal patterns, despite only one Wall Street analyst covering it. Tevogen Bio develops T-cell therapies for infectious diseases, cancers, and neurological disorders, with TVGN 489 completing Phase 1 trials for Long COVID and COVID-19. The stock has experienced significant price fluctuations, with lows likely due to tax loss selling and potential upside from the Santa Claus Rally and January effect.
Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?
On Thursday, Tevogen Bio Holdings Inc. TVGN announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion.
Tevogen Bio Holdings Inc. (G28) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tevogen Bio Holdings Inc. ever had a stock split?
Tevogen Bio Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ryan H. Saadi M.P.H, CEO | XFRA Exchange | US88165K1016 ISIN |
| US Country | 18 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Tevogen Bio Holdings Inc. is a pioneering force in the field of biotechnology, concentrating its efforts on the development of innovative T cell therapeutics tailored for various medical domains such as virology, oncology, and neurology. Situated in Warren, New Jersey, Tevogen stands out as a clinical-stage company that leverages cutting-edge technology to create off-the-shelf precision treatments. These advancements aim to fulfill the critical healthcare gaps faced by patients with acute conditions, including those affected by COVID-19 and its prolonged aftermath, known as long COVID. Through extensive research and development, Tevogen Bio harnesses the power of precision medicine to design therapies that are both impactful and accessible, reflecting their commitment to addressing some of the most pressing medical challenges of our time.
Products and Services
- TVGN 489
This lead investigational precision T cell product by Tevogen Bio Holdings Inc. is at the forefront of the company's innovative approach to combatting COVID-19. Specifically developed for patients at acute risk, TVGN 489 has emerged as a promising therapeutic strategy not only for those currently battling the infection but also for a particular group of individuals grappling with the lingering symptoms of long COVID. The underlying technology and methodology of TVGN 489 embody Tevogen’s commitment to precision healthcare, offering a beacon of hope for patients in need of effective and targeted interventions.
